« Study index
ReCAST-3 logo

ReCAST-3 trial

Remote ischaemic Conditioning After Stroke Trial 3

For further information please contact us.
Senior trial manager:
Chief investigator:
Nottingham stroke trials office:

Live database

Go to http://recast-3.ac.uk/live/ and use the ID and PIN given to you in your activation email.

You should have set your own password already.
Demonstration database

For practice, please go to and use the following credentials.
Password nottingham
Follow @ReCAST3Trial on Twitter / X logo
for the latest news and information.

Title Remote ischaemic Conditioning After Stroke Trial 3 (ReCAST-3)
Acronym ReCAST-3
Chief investigator Dr Tim England
Aim To perform a multicentre randomised controlled trial assessing remote ischaemic conditioning (RIC) in patients with acute ischaemic stroke.
Trial configuration Phase III prospective randomised (1:1) sham-controlled blinded-endpoint parallel-group multicentre trial.
Setting Adults with acute ischaemic stroke presenting in emergency departments and stroke units in the UK.
Sample size estimate Assuming alpha=0.05, power=90%, losses to follow up=5% and covariate adjustment reducing sample size by 20%, a sample size of 1,300 will be needed to detect a treatment effect of OR 0.75 by shift analysis of mRS.
Number of participants 1,300
Eligibility criteria Inclusions
  • Acute ischaemic stroke, within 24 hours of onset
  • Spontaneous intracerebral haemorrhage ruled out on baseline clinical neuroimaging
  • Haemorrhagic transformation of infarction (HTI) HI1, HI2, PH1 is permitted
  • NIHSS score between 5 and 25 (inclusive) at time of randomisation
  • At least 18 years old
  • Pre-morbid dependency (modified Rankin Scale of 4 or 5)
  • Spontaneous intracerebral haemorrhage
  • Systolic blood pressure below 80 mmHg
  • Haemorrhagic transformation of infarction PH2 (haematoma occupying 30% or more of the infarcted tissue, with obvious mass effect)
  • Pre-existing diagnosis of dementia
  • Coma (Glasgow Coma Scale below 8)
  • Malignancy
  • Significant co-morbidity (life expectancy of less than 6 months)
  • Glucose (BM stix or equivalent) less than 3 mmol/L
  • Known pregnancy
  • Taking part in another interventional trial, unless co-enrolment has been approved by both chief investigators and sponsor (co-enrolment in observational studies is generally accepted)
  • Seizure on presentation unless brain imaging identifies evidence of significant brain ischaemia (early ischaemic change or hyperdense vessel on CT scan, or angiography confirmed arterial occlusion)
  • Significant tissue injury of the upper limbs, which in the opinion of the investigator, will be exacerbated by remote ischaemic conditioning
  • Expected repatriation of the participant to another hospital not participating in ReCAST-3, where RIC or sham cannot continue
  • Mechanical thrombectomy substudy only
    Known contra-indication to administration of IV contrast (required for a CT Perfusion scan).  This may include previous allergic reaction to contrast or considered high risk for contrast induced nephropathy (at the discretion of the investigator).  This does not exclude them from the main trial.
Description of interventions
  • Remote ischaemic conditioning

    4 cycles of intermittent upper limb ischaemia – alternating 5 minutes inflation (+20 mmHg above systolic BP), followed by 5 minutes deflation of bilateral upper arm blood pressure cuffs.
  • Sham procedure

    Bilateral upper arm blood pressure cuffs are inflated to 50 mmHg for 4 cycles (5 minutes inflation/5 minutes deflation).
Duration of study Total trial duration 45 months.
Participant duration: 90±7 days.
Randomisation and blinding Web based randomisation will occur immediately after consent, performed by the clinician taking consent.  Randomisation will be 1:1 RIC: placebo, minimised on baseline prognostic factors.  Follow-up measures will be performed by assessors blinded to treatment allocation
Outcome measures Primary outcome: Death or dependency at day 90 (modified Rankin Scale [mRS], ordinal shift analysis) recorded using central blinded telephone follow-up.
Secondary outcomes (day 90): Cerebrovascular events; major adverse cardiac and cerebral events; acute kidney injury; COVID-19 status; disability; cognition; mood; frailty; quality of life; safety (death; neurological deterioration; intracranial haemorrhage, systemic embolism, serious adverse events).
Mechanisms: Mechanical thrombectomy sub-study (day 2-14 MRI; infarct growth and volume, oedema, perfusion).

Contact details
Address: Room S/D2108
Stroke Trials Unit
School of Medicine
University of Nottingham
Queen's Medical Centre
Derby Road
Nottingham NG7 2UH
United Kingdom

Tel: 0115 823 1770
Other documents

UoNStrokeAdara UoNStrokeAdara Switch to mobile site